BioSpace News Archive

At the back of these factors, along with increasing demand for minimally invasive and accurate biopsies, the global needle biopsy market is projected to cross a market value of US$ 1.2 Bn by the end of 2030.

The global surgical retractors market is expected to expand at a CAGR of 5% during the forecast period.

The global Biopharmaceutical Third-Party Logistics market size is expected to be worth around US$ 198.9 billion by 2030, according to a new report by Nova one advisor.

According to the current analysis of Reports and Data, the global Immunomodulators market was valued at USD 165.21 Billion in 2019 and is expected to reach USD 251.69 Billion by the year 2027, at a CAGR of 5.4 %.

Medical device company Theragen is pleased to announce the issuance of a U.S. Patent acknowledging its innovative approach to the development of the ActaStim-S Spine Fusion Bone Growth Stimulator system.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has initiated rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of the Company’s single-shot chikungunya vaccine candidate in persons aged 18 years and above.

Several advances in the field of biotechnology, particularly antibody engineering has led to designing of next generation therapeutics with more enhanced efficacy and safety.

Dermaliq Therapeutics, Inc. today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor.

According to the report, the global cord blood banking services market was valued at US$ 25.8 Bn in 2021 and is anticipated to expand at a CAGR of 10.9% from 2022 to 2030.

Sirnaomics Ltd. announced today that the Company has dosed the first patient in a Phase I/II clinical study of STP705, the Company’s leading siRNA (small interfering RNA) drug candidate, for the treatment of patients with facial squamous cell skin cancer in situ (isSCC).